Acurx Pharmaceuticals (ACXP)
NASDAQ:ACXP
Want to see ACXP full AI Analyst Report?
Top Page
Acurx Pharmaceuticals
(NASDAQ:ACXP)
Select Model
Select Model
Rating:44Neutral
Price Target:
$2.00
▼(-28.06% Downside)
Action:ReiteratedDate:04/16/26
The score is primarily weighed down by weak financial performance (no revenue, widening losses, and worsening cash burn in 2025), which elevates dilution/financing risk. Technicals are also soft with negative MACD and the stock below key moving averages. Corporate events add some offset via fresh financing and pipeline advancement, but valuation remains constrained by ongoing losses and no dividend support.
Positive Factors
Late-stage clinical positioning & regulatory designations
Ibezapolstat's Phase‑3 readiness plus FDA Fast Track and QIDP designations and favorable EMA guidance materially shorten development timelines and enhance regulatory predictability. These designations also support exclusivity and make the program more partnerable for commercialization and licensing.
Negative Factors
Pre-revenue with persistent and widening losses
The company remains pre‑revenue and reported substantially wider net losses in 2025, signaling deepening value erosion. Without commercial revenue, profitability depends entirely on successful clinical outcomes and licensing, leaving long‑term viability contingent on binary development milestones.
Read all positive and negative factors
Positive Factors
Negative Factors
Late-stage clinical positioning & regulatory designations
Ibezapolstat's Phase‑3 readiness plus FDA Fast Track and QIDP designations and favorable EMA guidance materially shorten development timelines and enhance regulatory predictability. These designations also support exclusivity and make the program more partnerable for commercialization and licensing.
Read all positive factors
Acurx Pharmaceuticals (ACXP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.23M
Dividend YieldN/A
Average Volume (3M)1.14M
Price to Earnings (P/E)―
Beta (1Y)-0.42
Revenue GrowthN/A
EPS Growth66.28%
CountryUS
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.73
Shares Outstanding3,671,093
10 Day Avg. Volume3,231,033
30 Day Avg. Volume1,135,368
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.71
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-1.04K
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda1.28K
Forecast
1Y Price Target
$17.00Price Target Upside511.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-3.27
Revenue Forecast (FY)N/A
Acurx Pharmaceuticals Business Overview & Revenue Model
Company Description
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that ha...
How the Company Makes Money
As a clinical-stage company, Acurx does not have established, recurring product revenue from marketed drugs. Its cash inflows have historically been driven primarily by financing activities (e.g., issuing equity) rather than operating revenue; spe...
Acurx Pharmaceuticals Earnings Call Summary
Earnings Call Date:Nov 12, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:May 12, 2026
Earnings Call Sentiment Neutral
The earnings call presented a mix of positive developments, such as achieving NASDAQ compliance, patent expansion, and successful presentations, alongside ongoing financial challenges and significant reductions in R&D expenses. The company's improved financial position and strategic scientific advancements were notable, though the net loss and reduced R&D spending highlight areas of concern.Positive Updates
NASDAQ Compliance Achieved
Acurx Pharmaceuticals effected a 1-for-20 reverse stock split, regaining compliance with NASDAQ listing rules with a minimum bid price of $1 per share and a stockholder equity threshold of $2.5 million.
Negative Updates
Decrease in R&D Expenses
Research and development expenses decreased significantly, from $1.2 million in Q3 2024 to $0.4 million in Q3 2025, primarily due to reductions in manufacturing and consulting costs.
Read all updates
Q3-2025 Updates
Positive
Negative
NASDAQ Compliance Achieved
Acurx Pharmaceuticals effected a 1-for-20 reverse stock split, regaining compliance with NASDAQ listing rules with a minimum bid price of $1 per share and a stockholder equity threshold of $2.5 million.
Read all positive updates
Company Guidance
During the third quarter of 2025, Acurx Pharmaceuticals provided several key updates regarding its financial performance and strategic activities. The company effected a 1-for-20 reverse stock split and regained compliance with NASDAQ's minimum bid price and stockholder equity requirements. Financially, Acurx ended the quarter with $5.9 million in cash, up from $3.7 million at the end of 2024, and raised an additional $1.7 million through an equity line of credit. Research and development expenses decreased to $0.4 million from $1.2 million in the same quarter the previous year, while general and administrative expenses remained flat at $1.6 million. The company reported a net loss of $2 million, or $1.23 per diluted share, compared to a $2.8 million loss, or $3.45 per share, in the prior year. Additionally, Acurx highlighted progress in its ibezapolstat program, including new patent grants, scientific publications, and presentations at industry conferences, while continuing to seek funding opportunities for a phase three clinical trial.Acurx Pharmaceuticals Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -8.09M | 0.00 | -14.58M | -12.09M | -12.81M |
| Net Income | -7.97M | -14.10M | -14.58M | -12.09M | -12.75M |
Balance Sheet | |||||
| Total Assets | 7.69M | 3.86M | 7.71M | 9.38M | 13.25M |
| Cash, Cash Equivalents and Short-Term Investments | 7.56B | 3.71M | 7.47M | 9.11M | 12.96M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 2.42M | 3.24M | 3.04M | 2.06M | 843.91K |
| Stockholders Equity | 5.27M | 615.12K | 4.67M | 7.32M | 12.41M |
Cash Flow | |||||
| Free Cash Flow | -6.79B | -10.38M | -9.80M | -7.54M | -5.01M |
| Operating Cash Flow | -6.79B | -10.38M | -9.80M | -7.54M | -5.01M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 10.64B | 6.62M | 8.16M | 3.70M | 14.80M |
Acurx Pharmaceuticals Technical Analysis
Negative
2.78
Price Trends
2.96
Negative
3.06
Negative
4.46
Negative
Market Momentum
-0.24
Positive
40.54
Neutral
26.14
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACXP, the sentiment is Negative. The current price of 2.78 is below the 20-day moving average (MA) of 3.49, below the 50-day MA of 2.96, and below the 200-day MA of 4.46, indicating a bearish trend. The MACD of -0.24 indicates Positive momentum. The RSI at 40.54 is Neutral, neither overbought nor oversold. The STOCH value of 26.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ACXP.
Acurx Pharmaceuticals Risk Analysis
Acurx Pharmaceuticals disclosed 54 risk factors in its most recent earnings report. Acurx Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Acurx Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $9.15M | -0.31 | -97.58% | ― | 0.07% | 46.20% | |
46 Neutral | $58.55M | -5.32 | -71.26% | ― | -20.00% | 62.69% | |
44 Neutral | $7.23M | -0.47 | -291.07% | ― | ― | 66.28% | |
41 Neutral | $5.14M | -0.82 | -420.31% | ― | -10.30% | -36.45% | |
39 Underperform | $824.18K | ― | -1302.82% | ― | ― | 99.09% |
* Healthcare Sector Average
ACXP
Acurx Pharmaceuticals
2.16
-6.11
-73.88%
IBIO
Ibio
1.69
0.66
64.08%
WINT
Windtree Therapeutics
0.03
-0.98
-97.50%
BRTX
BioRestorative Therapies
0.23
-1.56
-87.36%
LIXT
Lixte Biotechnology Holdings
3.50
2.24
177.78%
BOLT
Bolt Biotherapeutics
4.80
-2.22
-31.62%
Acurx Pharmaceuticals Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Acurx Pharmaceuticals Secures New Financing to Advance Pipeline
Positive
Apr 16, 2026
On April 15–16, 2026, Acurx Pharmaceuticals, Inc. entered into agreements for a registered direct offering and concurrent private placement of its securities, raising approximately $2.5 million in upfront gross proceeds and issuing common st...
Business Operations and StrategyExecutive/Board ChangesProduct-Related Announcements
Acurx Advances Ibezapolstat Program for Recurrent C. difficile
Positive
Mar 9, 2026
On March 9, 2026, Acurx Pharmaceuticals’ compensation committee approved voluntary 10% base-salary cuts for its top executives and a 10% reduction in cash retainers for non-employee directors, effective April 1, 2026, while leaving bonus tar...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.